Granza Bio

Reprogramming Immunity for Target-Specific Medicines

Y CombinatorWinter 2024ActiveHealthcareTherapeuticsSynthetic BiologyBiotechHealthcareTherapeutics

What they do

Problem

Many diseases such as cancer and autoimmunity persist because cytotoxic immune cells become exhausted and cannot deliver effective, targeted cell killing.

Solution

The company develops programmable immune therapeutics that re-arm immune cells with newly programmed “superkiller” attack particles to restore and enhance localized target-specific killing.

Who it's for

Biopharma companies and clinical care providers developing or administering immune-based therapies for patients with cancer or autoimmune disease.

Founders

Ashwin Nandakumar

Founder

Ashwin completed his PhD (DPhil) in Oncology at the University of Oxford. After completing his PhD, he began working as a Cancer Research UK post-doctoral researcher at Oxford University and also at the Institute of Cancer Research (ICR), London. He also brings experience setting up oncology clinical trials and working in oncology start-ups.

LinkedIn · X